Amit Singal, MD, medical director of the Liver Cancer Program at UT Southwestern Medical Center, discusses the current treatment landscape for patients with hepatocellular carcinoma (HCC) and how the treatments differ among patients caught in early-stage versus late-stage at the 2019 International Liver Cancer Association Annual Conference. For patients with HCC where the disease is caught during an early-stage, curative options are available, Singal says. These therapies include surgical resection of the liver, local ablation, and liver transplantation. These treatments can afford 5-year survival in over 60% of the patients.
However, Singal notes that patients found at a more intermediate- or advanced-stage of disease have different treatment options, including palliative therapies such as chemoembolization, radioembolization, radiation-based therapies, or systemic-based therapies.
Currently, there are no different treatment options for patients with HCC based on the ideology of the disease. For patients with nonalcoholic steatohepatitis (NASH)-related cirrhosis, for example, Singal concludes that the treatment options are that of the same for other ideologies of disease.
For more resources and information regarding anticancer targeted therapies in liver cancer:
0 Comments